Alphatec Holdings, Inc. Q4 2025 Earnings Call Summary

Strategic Performance Drivers - Achieved 25% annual revenue growth by leveraging a 100% spine-focused strategy in a disrupted market, prioritizing proceduralization over individual products [5] - Expanded the lateral addressable market by converting surgeons from traditional posterior approaches to the proprietary PTP (Prone Transpsoas) technique [5] - Utilized the EOS Edge imaging system as a 'gold standard' entry point to gain access to previously unreachable accounts, particularly in complex deformity cases [5] - Attributed 2025 success to an integrated ecosystem where EOS Insight adoption nearly doubles implant usage growth rates within six months [5] - Maintained a competitive moat through the SafeOp neuromonitoring platform, providing unique automated assessments of both nerve location and health [5] - Drove same-store sales growth of 20% in established territories, reflecting deep trust and a 'halo effect' that expands utilization across a surgeon's entire practice [5] 2026 Outlook and Strategic Initiatives - Projecting 2026 revenue of approximately $890 million, supported by mid-teens volume growth and low single-digit revenue-per-surgery increases [5] - Anticipating a shift in historical seasonality patterns as strong Q2 and Q3 deformity volumes moderate the traditional Q4 surge [5] - Planning a controlled release of the Valence platform in 2026 to integrate navigation and robotic precision directly into designed surgical workflows [5] - Targeting $20 million in free cash flow for 2026, marking a permanent transition to a self-funding business model that supports instrument and inventory growth [5] - Advancing a long-term partnership with Theradaptive to bring a next-generation BMP to market, projected to offer significantly faster bone formation [5] Operational and Structural Dynamics - Lapped 2024 cost rationalization actions, resulting in a 35% drop-through of incremental revenue to adjusted EBITDA in Q4 [5] - Identified a 120 basis point mix headwind in revenue per case due to the expansion of the international business, which carries lower average pricing [5] - Realized 120 basis points of SG&A leverage specifically from the depreciation of prior-year surgical instrument investments [5] - Noted that February 2025 represented the highest level of new surgeon growth in two years, signaling accelerating sales momentum [5] Q&A Session Summary - Management expects 2026 revenue seasonality to mirror 2025, with Q1 representing approximately 22.1% of annual sales [7] - EBITDA is expected to show higher drop-through in the first quarter compared to the annual average of 32% [7]